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Abstract
Maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 (four-event stack maize) was produced by
conventional crossing to combine four single events: MON 87427, MON 89034, MIR162 and MON 87411.
The genetically modified organism (GMO) Panel previously assessed the four single maize events and
four of the subcombinations and did not identify safety concerns. No new data on the single maize events
or the four subcombinations that could lead to modification of the original conclusions on their safety
were identified. The molecular characterisation, comparative analysis (agronomic, phenotypic and
compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional
assessment indicate that the combination of the single maize events and of the newly expressed proteins
and dsRNA in the four-event stack maize does not give rise to food and feed safety and nutritional
concerns. The GMO Panel concludes that the four-event stack maize, as described in this application, is
as safe as and nutritionally equivalent to its non-GM comparator and the non-GM reference varieties
tested. In the case of accidental release of viable grains of the four-event stack maize into the
environment, this would not raise environmental safety concerns. The GMO Panel assessed the likelihood
of interactions among the single events in the six maize subcombinations not previously assessed and
concludes that these are expected to be as safe as and nutritionally equivalent to the single events, the
previously assessed subcombinations and the four-event stack maize. The post-market environmental
monitoring plan and reporting intervals are in line with the intended uses of the four-event stack maize.
Post-market monitoring of food/feed is not considered necessary. The GMO Panel concludes that the
four-event stack maize and its subcombinations are as safe as its non-GM comparator and tested non-GM
reference varieties with respect to potential effects on human and animal health and the environment.
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Summary
Following the submission of application EFSA-GMO-NL-2017-144 under Regulation (EC) No 1829/2003
from Monsanto Company (referred to hereafter as the applicant), the Panel on Genetically Modified
Organisms of the European Food Safety Authority (referred to hereafter as GMO Panel) was asked to
deliver a Scientific Opinion on the safety of genetically modified glyphosate tolerant and insect resistant
maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 (referred to hereafter as ‘four-event stack
maize’) and its subcombinations independently of their origin, according to Regulation (EU) No 503/2013
(referred to hereafter as ‘subcombinations’). The scope of application EFSA–GMO–NL–2017–144 is for the
placing on the market of maize MON 87427 9 MON 89034 9 MIR162 9MON 87411 and all its
subcombinations independently of their origin for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to three of the events present in the four-
event stack maize. The safety of subcombinations occurring as segregating progeny in the harvested
grains of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 is evaluated in the context of the
assessment of the four-event stack maize. The safety of subcombinations that have either been or could
be produced by conventional crossing through targeted breeding approaches, and which can be bred,
produced and marketed independently of the four-event stack, are risk assessed separately in the
present scientific opinion.
The four-event stack maize was produced by conventional crossing to combine four single maize
events: MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein), MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins), MIR162 (expressing the
Vip3Aa20 and phosphomannose isomerase (PMI) proteins)) and MON 87411 (expressing the Cry3Bb1
and CP4EPSPS proteins, and the DvSnf7 dsRNA) to confer resistance to certain lepidopteran and
coleopteran pests and tolerance to glyphosate-containing herbicides.
The GMO Panel evaluated the four-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring (PMEM) of GM plants. The GMO Panel considered the information submitted in
application EFSA-GMO-NL-2017-144, additional information provided by the applicant during the risk
assessment, the scientific comments submitted by the Member States and the relevant scientific
literature.
The previous assessments of the single events MON 87427, MON 89034, MIR162, MON 87411 and
four of the subcombinations provided a basis for the assessment of the four-event stack maize and the
remaining six subcombinations. No safety concerns were identified by the GMO Panel in the previous
assessments. No safety issue concerning the four single maize events was identified by the updated
bioinformatic analyses, nor reported by the applicant since the publication of the previous GMO
Panel scientific opinions. Therefore, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
For the four-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analysis of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the PMEM plan
was also undertaken.
The molecular characterisation data establish that the events stacked in maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 have retained their integrity. Protein expression
analyses showed that the levels of the newly expressed proteins are similar in the four-event stack maize
and in the single events, except for the expected difference for the CP4 EPSPS protein levels resulting
from the combination of the MON 87427 and MON 87411 events, both producing CP4 EPSPS protein in
the four-event stack. No indications of interactions that may affect the integrity of the events and the
levels of the newly expressed proteins in this four-event stack maize were identified.
The comparative analysis of forage and grain composition and agronomic/phenotypic characteristics
identified no differences between maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 and the
non-GM comparator that required further assessment for food/feed safety or environmental impact.
The molecular characterisation, the comparative analysis and the outcome of the toxicological,
allergenicity and nutritional assessment indicate that the combination of the single maize events and of
the newly expressed proteins and dsRNA in the four-event stack maize does not give rise to food and
feed safety and nutritional concerns. The GMO Panel concludes that maize MON 87427 9
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MON 89034 9 MIR162 9 MON 87411, as described in this application, is as safe as and nutritionally
equivalent to the non-GM comparator and the commercial non-GM maize reference varieties (hereafter
‘non-GM reference varieties’) tested.
Considering the combined events and their potential interactions, the outcome of the comparative
analysis and the routes and levels of exposure, the GMO Panel concludes that maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 would not raise safety concerns in the case of
accidental release of viable GM maize grains into the environment.
Since no new safety concerns were identified for the four previously assessed subcombinations, and
no new data leading to the modification of the original conclusions on safety were identified, the GMO
Panel considers that its previous conclusions on these maize subcombinations remain valid. For the
remaining six subcombinations included in the scope of application EFSA-GMO-NL-2017-144, no
experimental data were provided. The GMO Panel assessed the possibility of interactions between the
events in the six subcombinations and concludes that these subcombinations would not raise safety
concerns. These subcombinations are therefore expected to be as safe as and nutritionally equivalent
to the single events, the previously assessed subcombinations and the four-event stack maize.
Given the absence of safety concerns for foods and feeds from maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 and its subcombinations, the GMO Panel considers that post-market monitoring
of these products is not necessary. The PMEM plan and reporting intervals are in line with the intended
uses of the four-event stack maize and its subcombinations. The literature searches did not identify
any relevant publications on maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411. In the
context of annual PMEM reports, the applicant could further improve future literature searches
according to the GMO Panel recommendations provided in this scientific opinion.
The GMO Panel concludes that maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 and its
subcombinations, as described in this application, are as safe as the non-GM comparator and the
tested non-GM reference varieties with respect to potential effects on human and animal health and
the environment.
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1. Introduction
The scope of application EFSA-GMO-NL-2017-144 is for food and feed uses, import and processing
in the European Union (EU) of the genetically modified (GM) herbicide-tolerant and insect-resistant
maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 and all its subcombinations independently
of their origin.
1.1. Background
On 24 May 2017, the European Food Safety Authority (EFSA) received from the Competent
Authority of The Netherlands application EFSA-GMO-NL-2017-144 for authorisation of maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 (hereafter referred to as ‘the four-event stack
maize’) (Unique Identifier MON–87427–79 9 MON–89Ø34–39 9 SYN-IR162-49 9 MON-87411-9),
submitted by Monsanto Europe S.A. (hereafter referred to as ‘the applicant’) according to Regulation
(EC) No 1829/20031.
Following receipt of application EFSA-GMO-NL-2017-144, EFSA informed the Member States (MS)
and the European Commission and made the summary of the application available to the public on the
EFSA website.2
European Food Safety Authority (EFSA) checked the application for compliance with the relevant
requirements of Regulation (EC) No 1829/2003 and Regulation (EU) No 503/20133 and, when needed,
asked the applicant to supplement the initial application. On 13 July 2017, EFSA declared the
application valid and made the application available to MS and the European Commission.
From the validity date, EFSA and its scientific Panel on Genetically Modified Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientific
opinion on application EFSA-GMO-NL-2017-144. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the EU Member States and European Commission (for further details, see the
section ‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU MSs, including national Competent Authorities within the meaning of Directive 2001/18/EC.4
The EU MSs had 3 months to make their opinion known on application EFSA-GMO-NL-2017-144 as of date
of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientific risk assessment of maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 and all its subcombinations independently of their origin according to the of
application EFSA-GMO-NL-2017-144.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation including the opinions of the nominated risk
assessment bodies of EU Member States.5
In addition to the present scientific opinion, EFSA and its GMO Panel were also asked to report on
the particulars listed under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003. The relevant
information is made available in the EFSA Register of Questions,6 including the information required
under Annex II to the Cartagena Protocol, a labelling proposal, a Post-Market Environmental
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online at the EFSA Register of Questions: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocume
ntsLoader?question=EFSA-Q-2017-00442
3 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorization of genetically
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
5 Opinions of the nominated risk assessment bodies of EU Member States can be found at the EFSA Register of Questions
(http://registerofquestions.efsa.europa.eu/roqFrontend/login), querying the assigned Question Number.
6 http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2017-00442
Assessment of maize MON 87427 3 MON 89034 3 MIR162 3 MON 87411 and subcombinations
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2019;17(11):5848
Monitoring (PMEM) plan as provided by the applicant; the method(s), validated by the Community
reference laboratory, for detection, including sampling, identification of the transformation event(s) in
the food-feed and/or foods-feeds produced from it and the appropriate reference materials.
2. Data and methodologies
2.1. Data
The GMO Panel based its scientific assessment of maize MON 87427 9 MON 89034 9 MIR162 9
MON 87411 on the valid application EFSA-GMO-NL-2017-144, additional information provided by the
applicant during the risk assessment, relevant scientific comments submitted by EU MSs and relevant
peer-reviewed scientific publications. As part of this comprehensive information package, the GMO
Panel received additional unpublished studies submitted by the applicant in order to comply with the
specific provisions of Regulation (EU) No 503/2013. A list of these additional unpublished studies is
provided in Appendix B.
2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU) No
503/2013, its applicable guidelines (EFSA GMO Panel, 2010a,b 2011a,b, 2015a), explanatory notes and
statements (EFSA, 2014, 2017a,b, 2019) for the risk assessment of GM plants. During its risk
assessment, the GMO Panel considered all additional unpublished studies as listed in Appendix B for
potential effects on human and animal health and the environment.
For the assessment of 90-day animal feeding studies, the GMO Panel took into account the criteria
included in the EFSA guidance (EFSA Scientific Committee, 2011) and the explanatory statement for its
applicability (EFSA, 2014).
The GMO Panel also assessed the applicant’s literature searches, which include a scoping review, in
accordance with the recommendations on literature searching outlined in EFSA (2010, 2017a, 2019).
In the frame of the contract OC/EFSA/GMO/2014/01, a contractor performed preparatory work and
delivered report on the methods applied by the applicant in performing statistical analyses.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2017-144 covers the four-event stack maize MON 87427 9 MON
89034 9 MIR162 9 MON 87411 and all its 10 subcombinations independently of their origin (Table 1).
The term ‘subcombination’ refers to any combination of up to three of the maize events
MON 87427, MON 89034, MIR162 and MON 87411.
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-NL-2017-144
Degree of
stacking
Events Unique identifier
Four-event
stack
MON 87427 9 MON 89034 9 MIR162 9
MON 87411
MON–87427–79 9 MON–89Ø34–39 9 SYN-IR162-49 9
MON-87411-9
Three-event
stacks
MON 87427 9 MON 89034 9 MIR162 MON–87427–79 9 MON–89Ø34–39 9 SYN-IR162-49
MON 87427 9 MON 89034 9 MON
87411
MON–87427–79 9 MON–89Ø34–39 9 MON-87411-9
MON 87427 9 MIR162 9 MON 87411 MON–87427–79 9 SYN-IR162-49 9 MON-87411-9
MON 89034 9 MIR162 9 MON 87411 MON–89Ø34–39 9 SYN-IR162-49 9 MON-87411-9
Two-event
stacks
MON 87427 9 MON 89034 9 MON–87427–79 9 MON–89Ø34–39
MON 87427 9 MIR162 MON–87427–79 9 SYN-IR162-49
MON 87427 9 MON 87411 MON–87427–79 9 MON-87411-9
MON 89034 9 MIR162 MON–89Ø34–39 9 SYN-IR162-49
MON 89034 9 MON 87411 MON–89Ø34–39 9 MON-87411-9
MIR162 9 MON 87411 SYN-IR162-49 9 MON-87411-9
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The safety of subcombinations occurring as segregating progeny in harvested grains of maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 is evaluated in the context of the assessment of
the four-event stack maize in Section 3.5 of the present scientific opinion.
‘Subcombination’ also covers combinations that have either been or could be produced by
conventional crossing through targeted breeding approaches (EFSA GMO Panel, 2011a). These are
maize stacks that can be bred, produced and marketed independently of the four-event stack maize.
These subcombinations are assessed in Section 3.5 of this scientific opinion.
The four-event stack maize was produced by conventional crossing to combine four single maize
events: MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein), MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins), MIR162 (expressing the
Vip3Aa20 and PMI proteins) and MON 87411 (expressing the CP4 EPSPS and Cry3Bb1 proteins, and
the DvSnf7 dsRNA) to confer resistance to certain lepidopteran and coleopteran pests and tolerance to
glyphosate-containing herbicides. It should be noted that the assessment of herbicide residues in
maize herbicide-tolerant crops relevant for this application has been investigated by the EFSA
Pesticides Unit (EFSA, 2018).
All four single maize events, the two-event stacks MON 87427 9 MON 89034, MON 87427 9
MIR162, and MON 89034 9 MIR162, and the three-event stack MON 87427 9 MON 89034 9 MIR162
have been previously assessed by the GMO Panel (see Table 2), and no safety concerns were
identified.
3.2. Updated information on single events7
Since the publication of the scientific opinions on the single maize events (see Table 2), no safety
issue concerning the four single events has been reported by the applicant.
Updated bioinformatic analyses for maize events MON 87427, MON 89034, MIR162 and MON 87411
confirms that no known endogenous genes were disrupted by any of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed CP4 EPSPS,
Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins confirm previous results indicating no
significant similarities to toxins and allergens. Updated bioinformatic analyses of the newly created
Open Reading Frames (ORFs) within the inserts or spanning the junctions between the insert and the
flanking regions for events MON 87427, MON 89034, MIR162 and MON 87411 confirmed previous
analyses (Table 2). These analyses indicate that the production of a new peptide showing significant
similarities to toxins or allergens for any of the events in maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 is highly unlikely.
According to Regulation (EU) No 503/2013, when silencing approaches by RNAi have been used in
GM plant applications, a bioinformatic analysis to identify potential ‘off target’ genes is required. The
applicant has followed the recommendations by the GMO Panel for an RNAi off-target search in the
four-stack maize expressing the DvSnf7 dsRNA.8,9 Updated bioinformatics analysis confirms previous
results that do not indicate an off-target effect of the DvSnf7 dsRNA expression that would need
further assessment.
Table 2: Single maize events and subcombinations of maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 previously assessed by the GMO Panel
Event Application or mandate EFSA Scientific Opinion
MON89034 EFSA-GMO-NL-2007-37 EFSA GMO Panel (2008)
MIR162 EFSA-GMO-DE-2010-82 EFSA GMO Panel (2012)
MON 87427 EFSA-GMO-BE-2012-110 EFSA GMO Panel (2015b)
MON 87411 EFSA-GMO-NL-2015-124 EFSA GMO Panel (2018)
MON 89034 9 MIR162 EFSA-GMO-NL-2016-131 EFSA GMO Panel (2019a,b)
MON 89034 9 MON 87427 EFSA-GMO-BE-2013-117 EFSA GMO Panel (2017a)
MIR1629 MON 87427 EFSA-GMO-NL-2016-131 EFSA GMO Panel (2019a,b)
MON 89034 9 MIR162 9 MON 87427 EFSA-GMO-NL-2016-131 EFSA GMO Panel (2019a,b)
7 Dossier. Part II – Sections 1.2.1.3 and 1.2.2.2; additional information on 6/12/2018 and 4/6/2019.
8 Annex II of the minutes of the 118th GMO plenary meeting (https://www.efsa.europa.eu/sites/default/files/event/171025-m.
pdf)
9 Dossier: Part II – Section 1.2.1.3; additional information on 6/12/2018.
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In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis for events MON 87427, MON 89034,
MIR162 and MON 87411 to microbial DNA. The likelihood and potential consequences of plant-to-
bacteria gene transfer are described in Section 3.4.4.2.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Systematic literature review10
The GMO Panel assessed the applicant’s literature searches on maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411, which included a scoping review, according to the guidelines given in EFSA
(2010, 2017a, 2019).
A systematic review as referred to in Regulation (EU) No 503/2013 has not been provided in
support to the risk assessment of application EFSA-GMO-NL-2017-144. Based on the outcome of the
scoping review, the GMO Panel agrees that there is limited value in undertaking a systematic review
for maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 at present.
Although the overall quality of the performed literature searches is acceptable, the GMO
Panel considers that the searches on maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411
could be improved. The GMO Panel therefore recommends the applicant to:
• ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientific terminology, common typos, translation issues);
• ensure that enough truncation is used and used consistently.
The literature searches did not identify any relevant publications on maize MON 87427 9
MON 89034 9 MIR162 9 MON 87411.
3.4. Risk assessment of the four-event stack maize MON 87427 3
MON 89034 3 MIR162 3 MON 87411
3.4.1. Molecular characterisation
In line with the requirements laid down by Regulation (EU) No 503/2013, the possible impact of the
combination of the events on the integrity of the events, the expression levels of the newly expressed
proteins or the biological functions conferred by the individual inserts are considered below.
3.4.1.1. Genetic elements and their biological functions
Maize events MON 87427, MON 89034, MIR162 and MON 87411 were combined by conventional
crossing to produce the four-event stack maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411.
The structure of the inserts introduced into the four-event stack maize is described in detail in the
respective EFSA scientific opinions (Table 2) and no new genetic modifications were involved. Genetic
elements in the expression cassettes of the single events are summarised in Table 3.
Intended effects of the inserts in maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 are
summarised in Table 4.
Based on the known biological functions of the newly expressed proteins (Table 4), the only
potential functional interactions at the biological level are among the Cry and Vip proteins.
10 Dossier: Part II – Section 7; additional information: 3/10/2018, 5/12/2018, 21/6/2019.
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Table 4: Characteristics and intended effects of the events stacked in maize MON 87427 9 MON
89034 9 MIR162 9 MON 87411
Event
Protein/
dsRNA
Donor organism and biological
function
Intended effects in GM plant
MON 87427 CP4 EPSPS Based on a gene from Agrobacterium
strain CP4 (Barry et al., 2001). 5-
enolpyruvylshikimate-3-phosphate
synthase (EPSPS) is an enzyme involved
in the shikimic acid pathway for aromatic
amino acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event MON87427 expresses the bacterial
CP4 EPSPS protein which confers tolerance
to glyphosate-containing herbicides as it has
lower affinity towards glyphosate than the
plant endogenous enzyme
MON 89034 Cry1A.105
Cry2Ab2
Based on a gene from B. thuringiensis
subsp. kurstaki and subsp. aizawai.
B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Schnepf et al., 1998; Ellis et al., 2002)
Based on a gene from B. thuringiensis
subsp. kurstaki. B. thuringiensis is an
insect pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al.,
1998; Ellis et al., 2002)
Event MON 89034 expresses a modified
version of the Cry1A-type protein.
Cry1A.105 is a protein toxic to certain
lepidopteran larvae feeding on maize
Event MON 89034 expresses the Cry2Ab2, a
protein toxic to certain lepidopteran larvae
feeding on maize
Table 3: Genetic elements in the expression cassettes of the events stacked in maize MON
87427 9 MON 89034 9 MIR162 9 MON 87411
Event Promoter 5’ UTR Transit peptide Coding region Terminator
MON 87427 35S (CaMV) – CTP2 (Arabidopsis
thaliana)
cp4 epsps
(Agrobacterium sp.)
nos
(Agrobacterium
tumefaciens)
MON 89034 35S (CaMV)
35S (FMV)
cab (Triticum
aestivum)
–
–
CTP (Zea mays)
cry1A.105 (Bacillus
thuringiensis)
cry2Ab2 (Bacillus
thuringiensis)
hsp17 (Triticum
aestivum)
nos
(Agrobacterium
tumefaciens)
MIR162 ZmUbiInt (Zea
mays)
ZmUbiInt (Zea
mays)
–
–
–
–
vip3Aa20 (Bacillus
thuringiensis)
pmi (Escherichia coli)
35S (CaMV)
nos
(Agrobacterium
tumefaciens)
MON 87411 35S (CaMV)
pIIG (Zea mays)
TubA (Oryza sativa)
–
cab (Triticum
aestivum)
TubA (Oryza
sativa)
–
–
CTP2 (Arabidopsis
thaliana)
snf7 (Diabrotica
virgifera virgifera)
cry3Bb1 (Bacillus
thuringiensis)
cp4 epsps
(Agrobacterium sp.)
E9 (Pisum
sativum)
hsp17 (Triticum
aestivum)
TubA (Oryza
sativa)
CaMV: cauliflower mosaic virus; FMV: figwort mosaic virus; CTP: chloroplast transit peptide.
(–): When no element was specifically introduced to optimise expression.
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3.4.1.2. Integrity of the events in the four-event stack11
The genetic stability of the inserted DNA over multiple generations in the single maize events MON
87427, MON 89034, MIR162 and MON 87411 was demonstrated previously (see Table 2). Integrity of
these events in maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 was demonstrated by
polymerase chain reaction (PCR) and sequence analysis that showed that the sequences of the events
(inserts and their flanking regions) in the four-event maize stack are identical to the sequences
originally reported for the four single events, thus confirming that the integrity of these events was
maintained in the four-event stack maize.
3.4.1.3. Information on the expression of the inserts12
CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 protein levels were analysed by
enzyme-linked immunosorbent assay (ELISA) in material harvested from field trials at five locations in
the USA in 2014. Samples analysed included leaves (V3-V4 and VT), roots (V3-V4 and R5), forage
(R5), pollen (R1) and grain (R6) both those treated and not treated with glyphosate. In order to
assess the changes in protein expression levels which may result from potential interactions between
Event
Protein/
dsRNA
Donor organism and biological
function
Intended effects in GM plant
MIR162 Vip3Aa20
PMI
Based on a gene from B. thuringiensis
strain AB88 (Estruch et al., 1996). In
addition to Cry proteins, B. thuringiensis
also produces insecticidal proteins during
its vegetative growth stage. These are
referred to as vegetative insecticidal
proteins (Fang et al., 2007)
Based on a gene from E. coli strain K-12.
PMI (phosphomannose isomerase)
catalyzes the isomerisation of mannose-
6-phosphate to fructose-6-phosphate
and plays a role in the metabolism of
mannose (Markovitz et al., 1967)
Event MIR162 expresses a modified version
of the B. thuringiensis vip3Aa1 gene, and
encodes Vip3Aa20, a protein toxic to certain
lepidopteran larvae feeding on maize
Event MIR162 expresses PMI, which is used
as selectable marker. Mannose normally
inhibits root growth, respiration and
germination. Transformed cells expressing
PMI are able to utilise mannose as a carbon
source (Negrotto et al., 2000)
MON 87411 DvSnf7
dsRNA
Cry3Bb1
CP4 EPSPS
Based on a gene from western corn
rootworm (WCR) (Diabrotica virgifera
virgifera LeConte). The full-length Snf7
protein is part of the intracellular protein
trafficking pathway (ESCRT) which is
important for the maintenance of a
functional intracellular transport of
transmembrane proteins (Baum et al.,
2007; Ramaseshadri et al., 2013)
Based on a gene from Bacillus
thuringiensis. B. thuringiensis is an
insect pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al.,
1998; Ellis et al., 2002)
Based on a gene from Agrobacterium
strain CP4 (Barry et al., 2001). 5-
enolpyruvylshikimate-3-phosphate
synthase (EPSPS) is an enzyme involved
in the shikimic acid pathway for aromatic
amino acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event MON87411 expresses DvSnf7 dsRNA
which is a small RNA toxic to western corn
rootworm feeding on maize
Event MON 87411 expresses the Cry3Bb1, a
protein toxic to certain coleopteran insects
Event MON87411 expresses the bacterial
CP4 EPSPS protein which confers tolerance
to glyphosate-containing herbicides as it has
lower affinity towards glyphosate than the
plant endogenous enzyme
11 Dossier: Part II—Section 1.2.2.3 and additional information on 6/12/2018.
12 Dossier: Part II—Section 1.2.2.3 and additional information on 6/12/2018, 9/4/2018, 4/6/2019.
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the events, protein levels were determined for the four-event stack and the corresponding single
events in different parts of the plant.
The levels of all the newly expressed proteins in the four-event stack maize and the corresponding
singles were comparable in all tissues, except for CP4 EPSPS protein levels expected to be different
because of the combination of events MON 87427 and MON 87411 both producing CP4 EPSPS in the
four-event stack maize (Appendix A). Therefore, there is no indication of an interaction that may affect
the levels of the newly expressed proteins in this stack.
The applicant provided a measure of the levels of DvSnf7 dsRNA in different tissues of the four-
event maize stack and the single event MON 87411 including grain and forage. However, the dsRNA is
an intermediate molecule which is processed by Dicer to siRNA molecules and the levels of dsRNA are
not a good proxy for the levels of the active siRNAs in the plant (Paces et al., 2017). Therefore, the
levels of the DvSnf7 dsRNA were not considered relevant for the risk assessment of maize MON
87427 9 MON 89034 9 MIR162 9 MON 87411.
3.4.1.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 have retained their integrity. Protein expression analyses showed that the
levels of the newly expressed proteins are comparable in the four-event stack and in the single events
except for the expected higher levels of CP4 EPSPS protein in the four-event stack maize. Therefore,
there is no indication of an interaction that may affect the integrity of the events or the levels of the
newly expressed proteins in this stack. In addition, the potential impact of the DvSnf7 dsRNA on the
levels of the newly expressed proteins was assessed by comparing the protein expression levels in the
four-event stack and the respective singles. The data indicate that there is no impact of the DvSnf7
dsRNA on the expression levels of the newly expressed proteins.
Based on the known biological function of the newly expressed proteins, the only potential
functional interactions are among the Cry and Vip proteins in susceptible insects, which will be
addressed in Section 3.4.4.
3.4.2. Comparative analysis13
3.4.2.1. Overview of studies conducted for the comparative analysis
Application EFSA-GMO-NL-2017-144 presents data on agronomic and phenotypic characteristics, as
well as on forage and grain composition of maize MON 87427 9 MON 89034 9 MIR162 9
MON 87411 (Table 5).
3.4.2.2. Experimental field trial design and statistical analysis
At each field trial site, the following materials were grown: the four-event maize, the comparator
MPA640B and four non-GM hybrid maize reference varieties (hereafter ‘non-GM reference varieties’).
Table 5: Overview of the comparative analysis studies to characterise the four-event stack maize in
application EFSA-GMO-NL-2017-144
Study focus Study details Comparator
Non-GM reference
varieties
Agronomic and phenotypic
analysis
Field study, USA, 2014, 2016, 8 sites(a) MPA640B Twenty(c)
Compositional analysis Field study, USA, 2014, 8 sites(b)
(a): The field trials conducted in 2014 were located in Jefferson, IO; Stark, IL; Clinton, IL; Clinton, IN; Seward NE and Lehigh,
PA. The field trials conducted in 2016 were located in Jefferson, IO and Perquimans, NC.
(b): The field trials were located in Jefferson, IO; Stark, IL; Clinton, IL; Vermilion, IL; Clinton, IN; Seward NE; Miami, OH and
Lehigh, PA.
(c): Non-GM maize varieties used in the agronomic, phenotypic and compositional field trials, with their corresponding relative
maturity indicated in brackets were Channel 211-97 (111), Dekalb DKC59-34 (109), Dekalb DKC62-06 (112), Gateway 6158
(115), LG2540 (108), LG2548 (108), LG2597 (112), Midland Phillips 7B15P (111), Mycogen 2H721 (112), Mycogen 2J790
(114), Mycogen 2M746 (113), NH6280 (112), NH6769 (115), Stewart S588 (112), Stewart S602 (112) and Stine 9724 (111).
Channel 213-88 (113), Stewart S480 (107), Stine 9628 (109) and Specialty 3656 (111) were used only for the agronomic and
phenotypic analysis where Dekalb DKC63-43 (113), NC+ 5220 (112) and Phillips 717 (109) for the compositional field trials only.
13 Dossier: Part II – Section 1.3; additional information: 8/08/2018, 11/12/2018 and 9/04/2019.
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All materials were treated with conventional herbicides management regimes; in addition, the field
trials included the four-event stack maize exposed to the intended glyphosate-containing herbicide on
top of the conventional herbicides.
The agronomic/phenotypic and compositional data were analysed as specified by EFSA GMO
Panel (2010b, 2011a). This includes, for each of the two treatments of maize MON 87427 9
MON 89034 9 MIR162 9 MON 87411, the application of a difference test (between the GM maize and
the comparator) and an equivalence test (between the GM maize and the set of non-GM reference
varieties).14 The results of the equivalence test are categorised into four possible outcomes (I–IV,
ranging from equivalence to non-equivalence).15
3.4.2.3. Suitability of selected test materials
Selection of the GM maize line and comparator
Event MON 87411 was originally produced in the inbred line LH244 (EFSA GMO Panel, 2018
_AP124). The remaining three single events were transferred in the genetic background of two non-
GM maize inbred lines: MIR162 was backcrossed into LH244; MON 87427 and MON 89039 into LH287.
In subsequent subsections, GM maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 refers
to hybrid obtained by crossing GM inbred line LH244 (carrying MIR162 and MON 87411) with GM
inbred line LH287 (carrying MON 87427 and MON 89034).
The comparator used in the field trials is the non-GM maize hybrid (MPA640B [= LH244 9 LH287]),
which has a genetic background similar to that of maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 (as documented by the pedigree), and is therefore considered to an
appropriate comparator.
Both maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 and the non-GM comparator
MPA640B belong to a relative maturity 112, which is considered appropriate for growing in
environments across North America, where the comparative field trials were conducted.
Selection of non-GM reference varieties
The 20 non-GM reference varieties with a relative maturity ranging from 107 to 115 were selected
by the applicant and at each field trial site four of them were tested (see Table 5). On the basis of the
information provided on relative maturity classes, the GMO Panel considers the selected non-GM
reference varieties appropriate for the comparative assessment.
Seed production and quality
The seeds of the four-event stack maize and the comparator used in the field trials (see Table 5)
were produced, harvested and stored under similar conditions, before being sown in the field trials.
The seed lots of the four-event stack maize and the comparator were verified for their purity via event
specific quantitative PCR analysis. The germination of four-event stack maize and the comparator was
tested under warm and cold temperature conditions. The GMO Panel considers that the starting seed
used as test material in the agronomic, phenotypic and compositional studies was of adequate quality.
Conclusion on suitability
The GMO Panel is of the opinion that the four-event stack maize, its comparator and the non-GM
reference varieties were properly selected and of adequate quality. Therefore, the test materials are
considered suitable for the comparative analysis.
3.4.2.4. Representativeness of the receiving environments
Selection of field trial sites
The selected field trial sites were located in commercial maize-growing regions of North America.
The soil characteristics of the selected fields were diverse,16 corresponding to optimal and near-optimal
conditions for maize cultivation (Sys et al., 1993). The GMO Panel considers that the selected sites
reflect commercial maize-growing regions in which the test materials are likely to be grown.
14 The purpose of the test of equivalence is to evaluate the estimated mean values for the GM crop taking into account natural
variability as defined by a set of non-GM references varieties with a history of safe use for consumption as food or feed.
15 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
16 Soil types of the field trials were clay loam, silty clay loam, loam and silt loam; soil organic matter ranged from 1.9% to 5.2%.
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Meteorological conditions
Maximum and minimum mean temperatures and sum of precipitations were provided on a monthly
basis. No exceptional weather conditions were reported at any of the selected field trial sites. The
GMO Panel considers that the meteorological data set falls within the range of climatic conditions
normally occurring at these sites.
Management practices
The field trials included plots containing the four-event stack maize, plots with the comparator and
plots with non-GM reference varieties, all managed according to local agricultural practices. In
addition, the field trials included plots containing four-event stack maize managed following the same
agricultural practices, plus exposed to the intended glyphosate-containing herbicide that was applied at
V3-V4 growth stage. The GMO Panel considers that the management practices including sowing,
harvesting and application of plant protection products were appropriate.
Conclusion on representativeness
The GMO Panel concludes that the geographical locations, soil characteristics, meteorological
conditions and management practices of the field trials are typical of the receiving environments where
the test materials could be grown.
3.4.2.5. Agronomic and phenotypic analysis
Thirteen17 agronomic and phenotypic endpoints plus information on abiotic stressors, disease
incidence and arthropod damage were collected from the field trials (Table 5). The endpoints dropped
ear count, stalk lodged plants and root lodged plants were not analysed as described in
Section 3.4.2.2 because of insufficient variability in the data.
The outcome of the analysis for the remaining 10 endpoints was as follows:
• For the four-event stack maize (not treated with the intended herbicide), statistically significant
differences with the non-GM comparator were identified for days to 50% pollen shed, days to
50% silking, ear height, grain moisture and yield. All these endpoints fell under equivalence
category I or II.
• For the four-event stack maize (treated with the intended herbicide), statistically significant
differences with the non-GM comparator were identified for early stand count, days to 50%
pollen shed, days to 50% silking, ear height and grain moisture. All these endpoints fell under
equivalence category I.
3.4.2.6. Compositional analysis
Maize forage and grains harvested from the field trial study in the USA in 2014 were analysed for
78 constituents (9 in forage and 69 in grain), including the key constituents recommended by OECD
(OECD, 2002). The statistical analysis was not applied to 15 grain constituents18 because more than
half of the observations were below the limit of quantification.
The statistical analysis was applied to the remaining 63 constituents (9 in forage19 and 54 in grain20);
a summary of the outcome of the test of difference and the test of equivalence is presented in Table 6.
• For the four-event stack maize (not treated with the intended herbicide), significant differences
with the non-GM comparator were identified for 47 endpoints (5 in forage and 42 in grain); of
17 Early stand count, days to 50% pollen shed, days to 50% silking, stay green, ear height, plant height, dropped ear count,
stalk lodged plants, root lodged plants, final stand count, grain moisture, test weight and yield.
18 Caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), myristic acid (C14:0), myristoleic acid (C14:1), pentadecanoic
acid (C15:0), pentadecenoic acid (C15:1), heptadecanoic acid (C17:0), heptadecenoic acid (C17:1), gamma-linolenic acid
(C18:3), eicosadienoic acid (C20:2), eicosatrienoic acid (C20:3), arachidonic acid (C20:4), sodium and furfural.
19 Ash, carbohydrates, protein, total fat, moisture, calcium, phosphorus, acid detergent fibre (ADF) and neutral detergent fibre
(NDF).
20 Proximates and fibre content (ash, carbohydrates, moisture, protein, total fat, acid detergent fibre (ADF), neutral detergent
fibre (NDF) and total dietary fibre (TDF)), minerals (calcium, copper, iron, magnesium, manganese, phosphorus, potassium
and zinc), vitamins (ß-carotene, thiamin, riboflavin, niacin, pyridoxine, folic acid and a-tocopherol), amino acids (alanine,
arginine, aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline,
serine, threonine, tryptophan, tyrosine and valine), fatty acids (palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid
(C18:0), oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), arachidic acid (C20:0), eicosenoic acid (C21:0) and
behenic acid (C22:0)) and other compounds (phytic acid, raffinose, ferulic acid and p-coumaric acid).
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those, ADF in forage fell under equivalence category III, while the other endpoints fell under
category I/II.
• For the four-event stack maize (treated with the intended herbicide), significant differences
with the non-GM comparator were identified for 35 endpoints (3 in forage and 32 in grain); all
of them fell under category I/II.
The GMO Panel assessed all the significant differences between the four-event stack maize and its
non-GM comparator, taking into account the potential impact on plant metabolism and the natural
variability observed for the set of non-GM maize reference varieties. Quantitative results for the
endpoints showing significant differences between the four-event stack maize and its non-GM
comparator and falling under equivalence category III/IV are given in Table 7.
3.4.2.7. Conclusions on the comparative analysis
Taking into account the natural variability observed for the set of non-GM reference varieties, the
GMO Panel concludes that:
Table 6: Outcome of the comparative compositional analysis of grains and forage from maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411. The table shows the number of
endpoints in each category
Test of difference(a)
Not treated(c) Treated(c)
Not
different
Significantly
different
Not
different
Significantly
different
Test of
equivalence(b)
Category I/II 15 46(d) 27 35(d)
Category III/IV – 1(e) – –
Not categorised 1(f) – 1(f) –
Total endpoints 63 63
(a): Comparison between the four-event stack maize and the non-GM comparator.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not treated with the intended glyphosate containing herbicide (see Section 3.4.2.4).
(d): Endpoints with significant differences between the four-event stack maize and its non-GM comparator and falling in
equivalence category I–II. For grains, for both treated and non-treated GM: carbohydrates, protein, total fat, ADF, NDF, TDF,
calcium, copper, magnesium, manganese, phosphorus, zinc, ß-carotene, niacin, pyridoxine, a-tocopherol, arginine, aspartic
acid, glycine, phenylalanine, threonine, tyrosine, iron, palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1), linoleic
acid (C18:2), eicosenoic acid (C21:0), raffinose, ferulic acid and p-coumaric acid. Only non-treated: alanine, glutamic acid,
histidine, isoleucine, leucine, lysine, proline, serine, tryptophan, valine and phytic acid. Only treated: linolenic acid (C18:3).
For forage, for both treated and non-treated GM: carbohydrates, calcium and phosphorus. Non-treated only: NDF.
(e): Endpoints with significant differences between the four-event stack maize and its non-GM comparator and falling in
equivalence category III/IV: ADF in forage (not treated only). Quantitative results are reported in Table 7.
(f): Endpoints not categorised for equivalence and without significant differences between the four-event stack maize and its
non-GM comparator: total fat in forage (both treated and not treated).
Table 7: Quantitative results (estimated means and equivalence limits) for compositional endpoints
in forage that are further assessed based on the results of the statistical analysis
Endpoint
Maize MON 87427 3 MON 89034 3
MIR162 3 MON 87411 Comparator
Non-GM reference varieties
Not treated(a) Treated(a) Mean Equivalence limits
ADF (% dw) 25.22* 23.86 23.42 22.94 20.87–25.01
dw: dry weight.
(a): Treated/not treated with the intended herbicide glyphosate.
For the four-event stack maize, significantly different values are marked with an asterisk, while the outcomes of the test of
equivalence are differentiated by greyscale backgrounds: white (equivalence category I or II), light grey (equivalence category
III) and dark grey (equivalence category IV).
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• None of the differences identified in agronomic and phenotypic characteristics tested between
the four-event stack maize and the non-GM comparator needs further assessment regarding
their potential environmental impact.
• None of the differences identified in forage and grain composition between the four-event
stack maize and the non-GM comparator needs further food/feed safety assessment except for
the change in levels of ADF in forage. This difference is further discussed in Section 3.4.3.
3.4.3. Food and Feed safety assessment21
3.4.3.1. Effect of processing
Maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 will undergo existing production
processes used for conventional maize. No novel production process is envisaged. Based on the
outcome of the comparative assessment, processing of the four-event stack maize into food and feed
products is not expected to result in products being different from those of conventional non-GM
maize varieties.
3.4.3.2. Influence of temperature and pH on newly expressed proteins
Effects of temperature and pH on the newly expressed proteins in this four-event stack maize have
been previously evaluated by the GMO Panel (Table 2).
3.4.3.3. Toxicology
Testing of newly expressed proteins
Six proteins (CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1) are newly expressed in
maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 (Section 3.4.1). The GMO Panel has
previously assessed these proteins in the context of the single events (Table 2), and no safety
concerns were identified for humans and animals. The GMO Panel is not aware of any new information
that would change this conclusion.
The potential for a functional interaction between the proteins newly expressed in maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 has been assessed with regard to human and
animal health. The insecticidal proteins Cry1A.105, Cry2Ab2 and Cry3Bb1 are delta-endotoxins acting
through cellular receptors found in target insect species. It is reported that the gastrointestinal tract of
mammals, including humans, lacks receptors with high specific affinity to Cry proteins (Hammond
et al., 2013; Koch et al., 2015). The Vip3Aa20 protein is a protein secreted by B. thuringiensis during
its vegetative phase acting in target insects via a mechanism similar to that of Cry proteins (Chakroun
et al., 2016; Bel et al., 2017). The CP4 EPSPS and PMI proteins are enzymes that catalyse distinct
biochemical reactions and act on unrelated substrates in the plant with high substrate specificity.
On the basis of the known biological function of the individual newly expressed proteins (Table 4),
there is currently no expectation for possible interactions relevant to the food and feed safety of maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411.
In vitro protein degradation studies on CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and
Cry3Bb1 proteins have been previously evaluated by the GMO Panel (Table 2).
The GMO Panel concludes that there are no safety concerns to human and animal health related to
the newly expressed proteins CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 in maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411.
Testing of new constituents other than newly expressed proteins
No new constituents other than newly expressed proteins have been identified in maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411, with the exception of the intended expression
of DvSnf7 dsRNA and derived siRNAs, designed to control coleopteran pests via RNAi. According to the
applicant, the gene-silencing effects of DvSnf7 dsRNA are mainly driven by ingestion of dsRNA from
the plant and its processing into siRNAs by the insects. The GMO Panel has previously assessed
DvSnf7 dsRNA and derived siRNAs in the context of the single event (Table 2), and no safety concerns
were identified for humans and animals. The GMO Panel is not aware of any new information that
would change this conclusion.
21 Additional information 4/6/2019 and additional information 16/10/2018, 13/11/2018, 4/06/2019, 21/06/2019, 20/08/2019.
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Information on altered levels of food and feed constituents
Acid detergent fibre (ADF) levels in forage were significantly different in maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 not treated with the conventional herbicide
when compared with its non-GM comparator and showed a lack of equivalence with the non-GM
reference varieties (Section 3.4.2.6). No toxicological concern is identified regarding this compositional
change. Further information on safety is provided in Section 3.4.3.6.
Testing of the whole genetically modified food and feed
Based on the outcome of the molecular characterisation, comparative analysis and toxicological
assessment, no indication of findings relevant to food/feed safety related to the stability and
expression of the inserts or to interaction between the transformation events, and no modifications of
toxicological concern in the composition of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411
have been identified (see Sections 3.4.1.4, 3.4.2.7 and 3.4.3. Therefore, animal studies on food/feed
derived from maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 are not necessary (EFSA
GMO Panel, 2011a).
In accordance to Regulation (EU) No 503/2013, the applicant provided a 90-day oral repeated-dose
toxicity study in rats on whole food and feed from each of the maize single-event MON 87427,
MON 89034, MIR162 and MON 87411. The four studies had already been provided in the context of
the single-event applications and assessed by the GMO Panel (Table 2); no adverse effects related to
the administration of the respective GM diets had been identified. In the context of the assessment of
maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 and in order to fulfil the requirements of
Regulation (EU) No 503/2013 for 90-day studies, upon EFSA’s request, the applicant provided
additional information for maize single events MON 87427, MON 89034 and MIR162.
The GMO Panel has previously assessed the above-mentioned additional information on
MON 87427, MON 89034 and MIR162 in the context of another applications under Regulation (EU)
503/2013 (EFSA GMO Panel, 2019a,b_AP131). The conclusion was that these studies are in line with
the requirements of Regulation (EU) 503/2013 and that there are no indications of adverse effects
related to the 90-day administration to rats of diets including up to 41.5% grains from maize
MON87427, MON89034 and MIR162.
3.4.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufficient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a; Regulation (EU) 503/2013). In addition, when known functional aspects of the
newly expressed protein or structural similarity to known adjuvants may indicate an adjuvant activity,
the possible role of these proteins as adjuvants is considered. When newly expressed proteins with a
potential adjuvant activity are expressed together, possible interactions increasing adjuvanticity and
impacting the allergenicity of the GM crop are assessed. Furthermore, an assessment of specific newly
expressed proteins in relation to their potential to cause celiac disease was also performed (EFSA GMO
Panel, 2017c).
Assessment of allergenicity of the newly expressed proteins
For allergenicity, the GMO Panel has previously evaluated the safety of CP4 EPSPS, Cry1A.105,
Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins individually, and no concerns on allergenicity were
identified in the context of the applications assessed (see Table 2). No new information on allergenicity
of these proteins that might change the previous conclusions of the GMO Panel has become available.
Based on the current knowledge, and as none of the newly expressed proteins showed allergenicity,
no reasons for concerns regarding the simultaneous presence of these newly expressed proteins in the
four-event stack maize affecting their allergenicity are expected.
For adjuvanticity, the Bt protein Cry1Ac has been suggested to possess adjuvant activity based on
animal studies when applied at relatively high doses (e.g. Vazquez et al., 1999; Santos-Vigil et al.,
2018). The Panel has previously evaluated the safety of Cry1A.105, Cry2Ab2, Vip3Aa20 and Cry3Bb1
proteins, and no concerns on adjuvanticity were identified in the context of the applications assessed
(see Table 2). More recently, this aspect has been discussed in detail by EFSA (EFSA, 2018; Parenti
et al., 2019). The levels of the individual Bt proteins in the four-event stack maize are comparable to
those in the respective single maize events (see Section 3.4.1.4). From the limited evidence available,
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the GMO Panel does not find indications that the presence of the Bt proteins at the levels expressed in
this four-event stack maize might act as adjuvants with the potential to enhance a specific
immunoglobulin E (IgE) response and to favour the development of an allergic reaction.
The applicant provided spontaneous information on the safety of the CP4 EPSPS, Cry2Ab2,
Cry1A.105 and Cry3Bb1 proteins regarding their potential hazard to cause a celiac disease
response.21,22 For such assessment, the applicant followed the principles described in the EFSA GMO
Panel guidance document (2017c). The assessment of the CP4 EPSPS and Cry2Ab2 proteins identified
no perfect or relevant partial matches with known celiac disease peptide sequences. The assessment
of the Cry1A.105 revealed partial matches which have been previously evaluated by the GMO
Panel (EFSA GMO Panel, 2019a_AP134). The assessment of the Cry3Bb1 proteins revealed partial
matches containing the Q/E-X1-P-X2 motif and requiring further investigations. Based on additional
considerations on position and nature of amino acids flanking the QLPV motif, such as the absence of
prolines at specific positions and the charge and size of adjacent amino acids (EFSA GMO
Panel, 2017c), the two relevant peptides containing the motif do not raise concern as they fail to
mimic gluten sequences. Therefore, no indications of safety concerns were identified by the GMO
Panel.
Assessment of allergenicity of GM plant products
The GMO Panel regularly reviews the available publications on food allergy to maize. However,
maize is not considered a common allergenic food23 (OECD, 2002). Therefore, the GMO Panel does not
request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.4.1, 3.4.2
and 3.4.3), the GMO Panel identifies no indications of a potentially increased allergenicity of food and
feed derived from this four-event stack maize with respect to that derived from the non-GM
comparator.
3.4.3.5. Dietary exposure assessment to new constituents
In line with Regulation (EU) No 503/2013, the applicant provided dietary exposure estimates to CP4
EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins newly expressed in
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 maize. Dietary exposure was estimated based on
protein expression levels reported in this application for the four-event stack maize treated with the
intended herbicide, the current available consumption data and feed practices, the foods and feeds
currently available in the market and the described processing conditions.
Dietary exposure to DvSnf7 dsRNA was not estimated, in line with the approach followed for the
single event (Table 2).
Table 8 describes the protein expression levels used to estimate both human and animal dietary
exposure.
22 It is pointed out that the requirements laid down in the recent EFSA guidance on allergenicity (2017) are not applicable to this
dossier, as described in Section 1.5 ‘Transition period’ of the guidance document.
23 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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Human dietary exposure24
Human dietary exposure was estimated across different European countries on different population
groups: young population (infants, toddlers, ‘other children’), adolescents, adult population (adults,
elderly and very elderly) and special populations (pregnant and lactating women).
For the purpose of estimating dietary exposure, the levels of newly expressed proteins in
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 maize grains were derived from replicated field
trials (four replicates from five locations) in the 2014 US growing season. Mean values (fresh weight
basis) are considered as the most to estimate dietary exposure (see Table 8). Since no specific
consumption data were available on commodities containing, consisting of or obtained from
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 maize grains, a conservative scenario with 100%
replacement of conventional maize by the GM maize was considered. Consumption figures for all
relevant commodities (e.g. corn flakes, sweet corn, popcorn, etc.) were retrieved from the EFSA
Comprehensive European Food Consumption Database (EFSA consumption database).25 Maize oil was
excluded from the assessment since no proteins are expected to be present in the oil.
For the acute dietary exposure estimations, the applicant directly assigned to processed
commodities the mean value reported for the concentration of the newly expressed proteins in maize
grains. This is a conservative approach as neither recipes nor the effect of processing on the final
concentration of newly expressed proteins are considered. Summary statistics from the EFSA
consumption database were used.26 Acute dietary exposure in high consumers within each dietary
survey and age class was estimated by summing the exposure derived from the 95th percentile
consumption for the dominant food commodity27 among consumers only and those exposures derived
from the mean consumption of the remaining food categories in the total population (EFSA, 2015).
Table 9 shows the highest acute dietary exposure for the different newly expressed proteins; highest
dietary exposure estimates ranged between 3.9 lg/kg body weight (bw) per day for PMI in adults
(18–65 years) and 373 lg/kg bw per day for Vip3Aa20 in toddlers (1–3 years). The most relevant food
commodities in terms of contribution to the exposure were sweet corn (toddlers) and popcorn (adults).
Table 8: Mean values (n = 20, lg/g dry weight and lg/g fresh weight) for newly expressed
proteins in grains and forage and pollen from MON 87427 9 MON 89034 9 MIR162 9
MON 87411 maize treated with the intended herbicide(a)
Protein
Tissue/developmental stage
Grains/R6 (lg/g dry weight
and lg/g fresh weight)
Pollen/R1
(lg/g fresh weight)(b)
Forage/R5
(lg/g dry weight)
CP4 EPSPS 13(c)/11 17 230
Cry1A.105 2.2(c)/2.0 5.4 15
Cry2Ab2 2.3(c)/2.0 0.4 47
Cry3Bb1 6.7(c)/5.9 31 62
PMI 1.3/1.1(d) 1.6(d) 5.2
Vip3Aa20 52/46(d) (d) 97
(a): Intended herbicide: glyphosate.
(b): Concentration values in pollen were adjusted to 6% moisture content before using them to estimate dietary exposure to the
different newly expressed protein via the consumption of pollen supplements (reported moisture content for pollen = 35%).
(c): Concentration values estimated originally in fresh weight were converted into lg/g dry weight using a standard dry weight
conversion factor (DWCF) of 0.88 to account for approximately 12% moisture content in the grains.
(d): Fresh weight values for Vip3Aa20 and PMI proteins used to estimate human dietary exposure were calculated by multiplying
the dry weight values by a DWCF of 0.88 to account for approximately 12% moisture content in the grains and by a factor
of 0.65 to account for approximately 35% moisture content in pollen.
24 Dossier: Part II – Section 2.4 and additional information 21/06/2019.
25 http://www.efsa.europa.eu/en/data/food-consumption-data
26 Summary statistics from the EFSA Comprehensive European Food Consumption Database accessed in September 2016.
27 Dominant food commodity refers to the food that will lead to the highest exposure among all consumed foods.
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The GMO Panel estimated chronic dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20,
PMI and Cry3Bb1 proteins. Individual consumption data of the relevant food commodities were
retrieved from the EFSA Consumption Database, using dietary surveys with at least 2 days
consumption and covering a total of 22 European countries.28 Different recipes and factors were
considered to estimate the amount of maize in the consumed commodities before assigning CP4
EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins levels to the relevant
commodities.29 No losses in the NEPs during processing were considered, except for certain
commodities excluded from the exposure estimations (maize oil, corn starch, corn syrup). The 95th
percentile chronic exposure (highly exposed population) was derived from the distribution of the
individual dietary exposure estimates within each dietary survey and age class.
Table 10 shows the chronic dietary exposure to each of the newly expressed proteins across
European dietary surveys; dietary exposure ranged between 0.03 lg/kg bw per day for PMI protein in
elderly population (65–74 years old) and 206.8 lg/kg bw per day for Vip3Aa20 protein in infants (< 1
year). Main average contributors to the exposure in the dietary surveys with the highest estimates
were sweet corn in infants, and cornflakes in toddlers and ‘other children’.
An ad hoc dietary exposure scenario was carried out for consumers of pollen supplements under
the assumption that these supplements are made of pollen from maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 (Table 11). Consumption data on pollen supplements were available for few
consumers across five different European countries;25 the low number of consumers available adds
uncertainty to the exposure estimations. Among consumers of pollen supplements, the average acute
dietary exposure would range from 0.003 lg/kg bw per day for Cry2Ab2 and 43.2 lg/kg bw per day
for Vip3Aa20, in the elderly population in both cases. Similarly, the average chronic dietary exposure
would range from 0.001 lg/kg bw per day for Cry2Ab2 and 28.8 lg/kg bw per day for Vip3Aa20, also
Table 9: Highest acute dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and
Cry3Bb1 proteins (lg/kg bw per day) estimated across European dietary surveys and
different age classes
Acute dietary exposure (lg/kg bw per day)
CP4 EPSPS Cry1A.105 Cry2Ab2 Cry3Bb1 Vip3Aa20 PMI
Toddlers 89 16.2 16.2 47.8 373 8.9
Adults 39 7.0 7.0 20.7 161 3.9
bw: body weight.
Table 10: Range of chronic dietary exposure estimates (95th percentiles, highly exposed
population) to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins
(lg/kg bw per day) across European dietary surveys and different age classes
Chronic dietary exposure (lg/kg bw per day)
N CP4 EPSPS Cry1A.105 Cry2Ab2 Cry3Bb1 Vip3Aa20 PMI
Infants 11 0.0–49.5 0.0–9.0 0.0–9.0 0.0–26.5 0.0–206.8 0.0–4.9
Toddlers 14 2.7–46.0 0.5–8.4 0.5–8.4 1.4–24.7 11.3–192.3 0.3–4.6
Other children 19 7.3–40.3 1.3–7.3 1.3–7.3 3.9–21.6 30.5–168.6 0.7–4.0
Adolescents 18 1.6–30.2 0.3–5.5 0.3–5.5 0.8–16.2 6.6–126.2 0.2–3.0
Adults 19 0.7–15.2 0.1–2.8 0.1–2.8 0.4–8.1 3.1–63.5 0.1–1.5
Elderly 18 0.3–9.3 0.1–1.7 0.1–1.7 0.1–5.0 1.2–39.1 0.03–0.9
Very elderly 14 0.0–8.7 0.0–1.6 0.0–1.6 0.0–4.7 0.0–36.3 0.0–0.9
Pregnant women 2 6.1–22.0 1.1–4.0 1.1–4.0 3.3–11.8 25.6–92.2 0.6–2.2
Lactating women 2 4.5–17.7 0.8–3.2 0.8–3.2 2.4–9.5 18.7–74.1 0.4–1.8
bw: body weight; N: number of dietary surveys.
28 Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Germany, Denmark, Estonia, Finland, France, United Kingdom, Greece,
Croatia, Hungary, Ireland, Italy, Latvia, Netherlands, Portugal, Spain, Romania, and Sweden.
29 100 grams of maize bread are made with approximately 74 g of maize flour, and a reverse yield factor of 1.22 from the
conversion of maize grains into flour is used. This results in 41.5 µg of Vip3Aa20 per gram of maize bread as compared to 46
µg/g in the maize grains.
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in the elderly population. Dietary exposure in high consumers of pollen supplements (based on 95th
percentile consumption) was not estimated as the limited consumption data available prevents from
deriving robust statistical estimates.
Animal dietary exposure24
Animal dietary exposure to CP4EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins
was estimated following the consumption of maize grain, gluten feed, gluten meal and maize forage/
silage since these are the maize products entering the feed chain. A conservative scenario with 100%
replacement of conventional maize products by the GM products was considered.
Mean levels of CP4EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins in maize grains
and forage/silage were derived from replicated field trial sites (five locations) in the 2014 US growing
season (Table 8). To estimate the mean NEP levels in maize gluten feed and gluten meal, a factor of 2.6
and 7.1 folds, respectively, was applied, based on the protein content of gluten feed and gluten meal
relative to maize grain (OECD, 2002), assuming that no losses of NEP occur during processing.
Dietary exposure to CP4EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1 proteins in maize
MON 87427 9 MON 89034 9 MIR162 9 MON87411 following the consumption of maize grain, gluten
feed and gluten meal was provided by the applicant across different animal species (i.e. broiler,
finishing swine and dairy cattle), based on estimates for animal body weight, daily feed intake and
inclusion rates (percentage) of maize grain, gluten feed and gluten meal in animal diets (OECD, 2009).
Estimated dietary exposure was calculated for each feed material and reported as the sum of their
consumption through diets, as detailed in Table 12.
The GMO Panel estimated dietary exposure to CP4EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and
Cry3Bb1 proteins across different livestock animal species (beef and dairy cattle, lamb, breeding swine
and layer) following the consumption of maize forage/silage, based on estimates for animal body
weight, daily feed intake and inclusion rates of maize forage/silage in animal diets (OECD, 2009).
Estimated dietary exposure in livestock is reported in Table 13.
Table 11: Dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1
proteins (lg/kg bw per day) in consumers of pollen across different age classes
Average exposure (lg/kg bw per day)
CP4 EPSPS Cry1A.105 Cry2Ab2 Cry3Bb1 Vip3Aa20 PMI
Chronic dietary exposure 0.1–12.1 0.02–3.9 0.001–0.3 0.1–22.8 0.1–28.8 0.01–1.2
Acute dietary exposure 0.1–18.1 0.04–5.9 0.003–0.4 0.2–34.2 0.3–43.2 0.01–1.8
bw: body weight.
Table 12: Dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1
proteins (lg/kg bw per day) in livestock
Dietary exposure (lg/kg bw per day)
CP4 EPSPS Cry1A.105 Cry2Ab2 Vip3Aa20 PMI Cry3Bb1
Broiler 1,532 259 271 6,130 153 790
Finishing swine 753 127 133 3,011 75 388
Dairy cattle 1,250 212 221 5,000 125 644
Table 13: Dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI and Cry3Bb1
proteins (lg/kg bw per day) in livestock
Dietary exposure (lg/kg bw per day)
CP4 EPSPS Cry1A.105 Cry2Ab2 Vip3Aa20 PMI Cry3Bb1
Beef cattle 4,416 288 902 1,862 100 1,190
Dairy cattle 5,307 346 1,085 2,238 120 1,430
Lamb 2,932 191 599 1,237 66 790
Breeding swine 1,061 69 217 448 24 286
Layer 1,574 103 321 664 35 424
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3.4.3.6. Nutritional assessment of endogenous constituents
The intended traits of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 are herbicide
tolerance and insect resistance, with no intention to alter nutritional parameters. However, levels of
ADF in forage (not treated) were significantly different from the non-GM comparator and showed a
lack of equivalence with the set of non-GM reference varieties (Section 3.4.2.6).
Animal nutrition
The increase in ADF percentage reported in Table 7 for the GM forage does not represent a safety
issue for animals. Herbivorous animals consume feed materials with high amount of fibre; therefore,
the minimal difference observed is not considered relevant. From these data, the GMO Panel concludes
that the nutritional impact of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411-derived food
and feed is similar to that expected from the non-GM comparator and non-GM reference varieties.
3.4.3.7. Conclusion on the food and feed safety assessment
The newly expressed proteins Cry1A.105, Cry2Ab, Cry3bB1, PMI, Vip3Aa20, CP4 EPSPS and the
DvSnf7 dsRNA and derived siRNAs in the four-event stack maize MON 87427 9 MON 89034 9 MIR162
9 MON 87411 do not raise safety concerns for human and animal health. No interactions between the
newly expressed proteins relevant for food and feed safety were identified. Similarly, the GMO
Panel did not identify indications of safety concerns regarding allergenicity or adjuvanticity related to
the presence of the newly expressed proteins in maize MON 87427 9 MON 89034 9 MIR162 9
MON 87411, or regarding the overall allergenicity of this four-event stack maize. Based on the
outcome of the comparative assessment and the nutritional assessment, the GMO Panel concludes that
the nutritional impact of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411-derived food and
feed is expected to be the same as those derived from the non-GM comparator and non-GM reference
varieties. The GMO Panel concludes that four-event stack maize MON 87427 9 MON 89034 9 MIR162
9 MON 87411 as described in this application, is nutritionally equivalent to and as safe as the non-GM
comparator and the non-GM reference varieties tested.
3.4.4. Environmental risk assessment30
Considering the scope of application EFSA-GMO-NL-2017-144, which excludes cultivation, the
environmental risk assessment (ERA) of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411
mainly takes into account: (1) the exposure of microorganisms to recombinant DNA in the
gastrointestinal tract of animals fed GM material and of microorganisms present in environments
exposed to faecal material of these animals (manure and faeces); and (2) the accidental release into
the environment of viable maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 grains during
transportation and/or processing (EFSA GMO Panel, 2010b).
3.4.4.1. Persistence and invasiveness of the GM plant
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2003). Field observations indicate that
maize grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent
crops (e.g. Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers
have been shown to grow weakly and flower asynchronously with the maize crop (Palaudelmas et al.,
2009). Thus, the establishment and survival of feral and volunteer maize in the EU is currently limited
and transient.
It is unlikely that the intended traits of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411
will provide a selective advantage to maize plants, except when they are exposed to glyphosate-
containing herbicides or infested by insect pests that are susceptible to the DvSnf7 dsRNA or to the
Cry1A.105, Cry2Ab2, Vip3Aa20 and/or Cry3Bb1 proteins. However, this fitness advantage will not allow
the GM plant to overcome other biological and abiotic factors (described above) limiting plant’s
persistence and invasiveness. Therefore, the presence of the intended traits will not affect the
persistence and invasiveness of the GM plant.
30 Dossier: Part II – Section 5; additional information 4/6/2019.
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In conclusion, the GMO Panel considers it very unlikely that maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 will differ from conventional maize hybrid varieties in its ability to survive until
subsequent seasons, or to establish occasional feral plants under European environmental conditions in
case of accidental release into the environment of viable maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 grains.
3.4.4.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer (HGT) of DNA or through vertical gene flow via cross-
pollination from feral plants originating from spilled grains.
Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel Scientific Opinions for the single events (see Table 2). This assessment included
consideration of homology-based recombination processes, as well as non-homologous end joining and
microhomology-mediated end joining. Possible fitness advantages that the bacteria in the receiving
environments would gain from acquiring recombinant DNA were considered. No concern was identified
in regard to an unlikely, but theoretically possible, HGT of the recombinant genes to bacteria in the gut
of domesticated animals and humans fed GM material or other receiving environments.
The applicant submitted an updated bioinformatic analysis for each of the single events to assess
the possibility for HGT by homologous recombination.
The updated bioinformatics analyses of events MON 87427, MON 89034, MIR162 and MON 87411
do not reveal any new DNA sequence that could provide sufficient length and identity which could
facilitate HGT by double homologous recombination, confirming the conclusions of previous Scientific
Opinions (EFSA GMO Panel, 2018_AP124, 2019a_AP134).
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage were not
identified.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this four-event stack maize to bacteria does not raise any environmental
safety concern.
Plant-to-plant gene transfer
The potential for occasional feral GM maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411
plants originating from grain import spills to transfer recombinant DNA to sexually compatible plants
and the environmental consequences of this transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
flowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA,
2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes, and/or maize-teosinte hybrids, occurring in cultivated areas
(EFSA, 2016; Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.4.4.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is
considered extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the
opinion that environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe will not differ from that of conventional maize varieties.
3.4.4.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-NL-2017-144 (no cultivation), potential interactions of
occasional feral four-event stack maize plants arising from grain import spills with the target organisms
are not considered a relevant issue.
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3.4.4.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled four-event stack maize grains is limited, and because ingested
dsRNA and proteins are degraded before entering the environment through faecal material of animals
fed GM maize, potential interactions of the four-event stack maize with non-target organisms are not
considered by the GMO Panel to raise any environmental safety concern. Interactions that may occur
among the Cry and Vip proteins (as mentioned in Section 3.4.1.4) will not alter this conclusion.
3.4.4.5. Interactions with abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled grains or occasional feral four-event stack maize
plants arising from grain import spills is limited, and because ingested dsRNA and proteins are
degraded before entering the environment through faecal material of animals fed GM maize, potential
interactions with the abiotic environment and biogeochemical cycles are not considered by the GMO
Panel to raise any environmental safety concern.
3.4.4.6. Conclusion of the environmental risk assessment
The GMO Panel concludes that it is unlikely that the four-event stack maize would differ from
conventional maize varieties in its ability to persist under European environmental conditions.
Considering the scope of the application EFSA-GMO-NL-2017-144, interactions of occasional feral four-
event stack maize plants with the biotic and abiotic environment are not considered to be relevant
issues. The analysis of HGT from the four-event stack maize to bacteria does not indicate a safety
concern. Therefore, considering the combined traits and their interactions, the outcome of the
comparative analysis, and the routes and levels of exposure, the GMO Panel concludes that the four-
event stack maize would not raise safety concerns in the event of accidental release of viable GM
maize grains into the environment.
3.4.5. Conclusion on the four-event stack maize MON 87427 3 MON 89034 3
MIR162 3 MON 87411
No new data on the four single maize events MON 87427, MON 89034, MIR162 and MON 87411
that would lead to a modification of the original conclusions on their safety were identified.
The combination of maize events MON 87427, MON 89034, MIR162 and MON 87411 in the four-
event stack maize did not give rise to issues concerning the molecular, agronomic/phenotypic or
compositional characteristics of the four-event stack maize that would be of concern for food and feed
safety and nutrition.
The newly expressed proteins and the DvSnf7 dsRNA in the four-event stack maize do not raise
safety concerns for human and animal health and the environment in light of the scope of this
application.
No indications of interactions between the events based on the biological functions of the newly
expressed proteins that would raise a safety issue were identified in maize MON 87427 9 MON 89034
9 MIR162 9 MON 87411. Comparison of the levels of the newly expressed proteins between the four-
event stack maize and those of the single maize events did not reveal an interaction at protein
expression level. In addition, the potential impact of the DvSnf7 dsRNA on the levels of the newly
expressed proteins was assessed by comparing the protein expression levels in the four-event stack
and the respective singles. The data indicate that there is no impact of the DvSnf7 dsRNA on the
expression levels of the newly expressed proteins.
Considering the combined traits and their potential interactions, the outcome of the comparative
analysis and the routes and levels of exposure, the GMO Panel concludes that maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 would not raise safety concerns in the event of
accidental release of viable GM maize grains into the environment.
No scientific information that could change the conclusions on this four-event stack maize was
retrieved through systematic literature searches covering the 10 years before submission of the
application and the period since the time of validity of the application. The GMO Panel concludes that
maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411, as described in this application, is
nutritionally equivalent to and as safe as the comparator and the non-GM reference varieties tested.
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3.5. Risk assessment of the subcombinations
Subcombinations previously assessed in the frame of other applications are discussed in
Section 3.5.1. The strategy followed for the subcombinations that have not been previously assessed
(Section 3.5.2) has been described by the GMO Panel.31 In this case, the risk assessment takes as its
starting point the assessment of the single maize events, and uses the data generated for the four-
event stack as well as all the additional data available on subcombinations previously assessed by the
GMO Panel (Table 2).
3.5.1. Subcombinations previously assessed
The GMO Panel has previously assessed four subcombinations and no safety concerns were
identified the two-event maize stacks MON89034 9 MON87427, MON 89034 9 MIR162; and
MON87427 9 MIR162, and the three-event stack maize MON 87427 9 MON 89034 9 MIR162 (see
Table 2). Literature searches covering the 10 years before submission of the application (January
2006–June 2018) and the period since the time of validity of the application revealed no new scientific
information relevant to the risk assessment of these maize stacks.32 Consequently, the GMO
Panel considers that its previous conclusions on these subcombinations remain valid.
3.5.2. Subcombinations not previously assessed
Six of the 10 subcombinations included in the scope of this application have not been previously
assessed by the GMO Panel, and no experimental data were provided for these maize stacks (see
Table 14).
3.5.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the four single maize events
was demonstrated previously (see Table 2). Integrity of the events was demonstrated in the four-event
stack maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 (Section 3.4.1.2) and the previously
assessed maize subcombinations (EFSA GMO Panel, 2017a,b, 2019a,b). The GMO Panel finds no
reasons to expect the loss of integrity of the events in the maize subcombinations not previously
assessed (see Table 14).
3.5.2.2. Expression of the events
The GMO Panel assessed whether any combination of the four events by conventional crossing
could result in significant changes in expression levels of the newly expressed proteins, as this could
indicate an unexpected interaction between the events. Based on current knowledge of the molecular
elements introduced, there is no reason to expect interactions that would affect the levels of the newly
expressed proteins in the six subcombinations compared with those in the single maize events. This
assumption was confirmed by comparing the levels of the newly expressed proteins of each single
maize event with those of the four-event stack maize. The levels were similar in the four-event stack
maize and in the single events except for CP4 EPSPS, which showed, in general, the expected higher
level in the stack resulting from the combination of the single events MON 87427 and MON 87411
(Section 3.4.1.3 and Appendix A). In addition, the potential impact of the DvSnf7 dsRNA on the levels
Table 14: Maize stacks not previously assessed and covered by the scope of application EFSA GMO
NL-2017-144
Degree of stacking Events
Three-event stack MIR162 9 MON 87427 9 MON 87411
MON 89034 9 MON 87427 9 MON 87411
MON 89034 9 MIR162 9 MON 87411
Two-event stack MON 87427 9 MON 87411
MIR162 9 MON 87411
MON 89034 9 MON 87411
31 115th GMO Panel meeting (Annex 1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
32 Dossier: Part II – Section 7; additional information: 8/08/2018.
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of the newly expressed proteins was assessed by comparing the protein expression levels in the four-
event stack and the respective singles. The data indicate that there is no impact of the DvSnf7 dsRNA
on the expression levels of the newly expressed proteins. This supports the conclusion that interactions
affecting the expression levels of the newly expressed proteins are not expected in the six
subcombinations not previously assessed and included in the scope of application EFSA-GMO-NL-2017-
144.
3.5.2.3. Potential functional interactions between the events
The GMO Panel assessed the potential for interactions between maize events in the six
subcombinations not previously assessed (Table 14), taking into consideration intended traits and
unintended effects.
Based on the known biological functions of the individual newly expressed proteins and dsRNA
(Table 4), there is currently no expectation for possible interactions relevant for the food and feed or
environmental safety between these proteins in those subcombinations. The GMO Panel took into
account all the intended and potential unintended effects considered in the assessment of the four
single events, the previously assessed subcombinations (Table 2) and the four-event stack maize. It is
concluded that none of these events would raise safety concerns when combined in any of these
maize subcombinations. The GMO Panel considers that no further data are needed to complete the
assessment of subcombinations from the four-event stack maize.
3.5.3. Conclusion
Since no new safety concerns were identified for the previously assessed subcombinations, the
GMO Panel considers that its previous conclusions on these maize subcombinations remain valid. For
the remaining six subcombinations included in the scope of application EFSA-GMO-NL-2017-144, no
experimental data have been provided. For these subcombinations, the GMO Panel assessed the
possibility of interactions between the events and concluded that these combinations would not raise
safety concerns. These subcombinations are therefore expected to be as safe as and nutritionally
equivalent to the single maize events, the previously assessed subcombinations and the four-event
stack maize.
3.6. Post-market monitoring
3.6.1. Post-market monitoring of GM food/feed
The GMO Panel concluded that the four-event stack maize, as described in this application, is
nutritionally equivalent to and as safe as the non-GM comparator and the non-GM reference varieties
tested (Section 3.4.3.7). Four of the subcombinations have been previously assessed and no safety
concerns were identified. The six subcombinations not previously assessed and included in the scope
of application EFSA GMO NL 2017 144 are expected to be as safe as and nutritionally equivalent to the
single maize events, the previously assessed maize subcombinations and the four-event stack maize
(Section 3.5.3). Therefore, the GMO Panel considers that post-market monitoring of food and feed
from the four-event stack maize and its subcombinations, as described in this application, is not
necessary.
3.6.2. Post-market environmental monitoring33
The objectives of a PMEM plan, according to Annex VII of Directive 2001/18/EC, are: (1) to confirm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct; and (2) identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus, a final adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientific rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from the four-event stack
mazie, no case-specific monitoring is required.
33 Dossier: Part II – Section 6.
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The PMEM plan proposed by the applicant for the four-event stack maize includes: (1) the
description of a monitoring approach involving operators (federations involved in import and
processing), reporting to the applicant, via a centralised system, any observed adverse effect(s) of
GMOs on human health and the environment; (2) a coordinating system established by EuropaBio for
the collection of information recorded by the various operators; and (3) the review of relevant
scientific publications retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The
applicant proposes to submit a PMEM report on an annual basis and a final report at the end of the
authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of the four-event stack maize. The GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plan. The PMEM plan and reporting intervals are in line
with the intended uses of the four-event stack maize and its subcombinations.
In the context of annual PMEM reports, the applicant should improve future literature searches
according to the GMO Panel recommendations given in Section 3.3.
3.6.3. Conclusions on post-market monitoring
No post-market monitoring of food and feed is necessary. The scope of the PMEM plan provided by
the applicant and the reporting intervals are in line with the intended uses of maize
MON 87427 9 MON 89034 9 MIR162 9 MON 87411.
4. Overall conclusions
The GMO Panel was asked to carry out a scientific assessment of maize MON 87427 9 MON 89034
9 MIR162 9 MON 87411 and subcombinations for import, processing and food and feed uses in
accordance with Regulation (EC) No 1829/2003.
No new information on the four single maize events MON 87427, MON 89034, MIR162 and
MON 87411 that would lead to a modification of the original conclusions on their safety were
identified.
The molecular characterisation, the comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins and the dsRNA in
the four-event stack maize does not give rise to food/feed safety and nutritional concerns. The GMO
Panel concludes that the four-event stack maize, as described in this application, is as safe as and
nutritionally equivalent to its non-GM comparator and the non-GM reference varieties tested.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from the four-event stack maize into the environment.
Since no new data on the four subcombinations previously assessed that would lead to a
modification of the original conclusions on their safety were identified, the GMO Panel considers that
its previous conclusions on these maize stacks remain valid. For the remaining six subcombinations
included in the scope of application EFSA-GMO-NL-2017-144, no information has been provided. The
GMO Panel assessed possible interactions between the events in the six subcombinations, and
concludes that these combinations of events MON 87427, MON 89034, MIR162, and MON 87411
would not raise safety concerns. These subcombinations are therefore expected to be as safe as and
nutritionally equivalent to the maize single events, the previously assessed subcombinations and the
four-event stack maize.
The literature searches did not identify any relevant publications on maize MON 87427 9 MON
89034 9 MIR162 9 MON 87411. In the context of annual PMEM reports, the applicant could further
improve future literature searches according to the GMO Panel recommendations.
In addition, the GMO Panel considered the additional unpublished studies listed in Appendix B. This
new information does not raise any concern for human and animal health and the environment
regarding the four-event stack maize and its subcombinations.
Given the absence of safety and nutritional concerns for foods and feeds from the four-event stack
maize and all its subcombinations, the GMO Panel considers that PMM of these products is not
necessary. The PMEM plan and reporting intervals are in line with the intended uses of the four-event
stack maize and its subcombinations.
In conclusion, the GMO Panel considers that maize MON 87427 9 MON 89034 9 MIR162 9
MON 87411 and its subcombinations, as described in this application, are as safe as the non-GM
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comparator and the tested non-GM reference varieties with respect to potential effects on human and
animal health and the environment.
Documentation as provided to EFSA
• Letter from the Competent Authority of Netherlands received on 24 May 2017 concerning a
request for authorisation of the placing on the market of maize MON 87427 9 MON 89034 9
MIR162 9 MON 87411 (EFSA-GMO-NL-2017-144) submitted in accordance with Regulation
(EC) No 1829/2003 by Monsanto Europe S.A./N.V.
• Application EFSA-GMO-NL-2017-144 validated by EFSA, 13 July 2017.
• Application stopped due to single event, 13 July 2017.
• Application restarted following adoption of single event, 31 May 2018.
• Request for supplementary information to the applicant, 07 June 2018.
• Request for supplementary information to the applicant, 07 June 2018.
• Request for supplementary information to the applicant, 02 August 2018.
• Receipt of supplementary information from the applicant, 08 August 2018.
• Receipt of supplementary information from the applicant, 24 September 2018.
• Receipt of supplementary information from the applicant, 03 October 2018.
• Request for supplementary information to the applicant, 15 October 2018.
• Receipt of supplementary information from the applicant, 16 October 2018.
• Request for supplementary information to the applicant, 08 November 2018.
• Receipt of supplementary information from the applicant, 13 November 2018.
• Request for supplementary information to the applicant, 15 November 2018.
• Receipt of supplementary information from the applicant, 05 December 2018.
• Receipt of supplementary information from the applicant, 06 December 2018.
• Receipt of supplementary information from the applicant, 11 December 2018.
• Request for supplementary information to the applicant, 05 February 2019.
• Receipt of supplementary information from the applicant, 09 April 2019.
• Request for supplementary information to the applicant, 18 April 2019.
• Request for supplementary information to the applicant, 22 May 2019.
• Receipt of supplementary information from the applicant, 04 June 2019.
• Receipt of supplementary information from the applicant, 21 June 2019.
• Receipt of spontaneous information from the applicant, 22 August 2019.
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ADF acid detergent fibre
CaMV cauliflower mosaic virus
CTP Chloroplast transit peptide
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
FMV Figwort Mosaic Virus
GM genetically modified
GMO genetically modified organism
GMO Panel EFSA Panel on Genetically Modified Organisms
HGT horizontal gene transfer
HR homologous recombination
IgE immunoglobulin E
NDF neutral detergent fibre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PCR polymerase chain reaction
PMEM post-market environmental monitoring
PMI phosphomannose isomerase
TDF total dietary fibre
UTR untranslated region
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Appendix A – Protein expression data
Means, standard deviation and ranges of protein levels (lg/g dry weight) from maize MON 87427 9
MON 89034 9 MIR162 9 MON 87411 (treated with glyphosate), MON 87427 (treated with glyphosate),
MON 89034 (not treated), MIR162 (not treated) and MON 87411 (treated with glyphosate), from field
trials performed across five locations in USA in 2014(a)
Protein Event(s)
Leaf
(V3-V4)
Leaf (VT)
Root
(V3-V4)
Forage
Root
(R5)
Forage
(R5)
Pollen
(R1)
Grain
(R6)
CP4
EPSPS
MON 87427 9
MON 89034 9
MIR162 9
MON 87411
940(b)  310(c)
150–1,500(d)
1,000  140
730–1,300
260  56
170–360
190  41
110–280
230  63
140–340
26  4.3
20–33
13  1.7
8.2–16
MON87427 870  130
700–1,300
870  86
680–1,100
200  53
120–300
160  40
76–230
180  44
96–270
N/A 8.6  1.3
6.1–11
MON87411 56  7.3
43–69
45  2.8
41–53
51  16
27–81
21  9.3
5.7–38
12  3.4
6.7–19
23  3.0
17–28
4.4  0.49
3.5–5.3
Cry1
A.105
MON 87427 9
MON 89034 9
MIR162 9
MON 87411
200  46
130–290
88  37
50–180
48  15
29–85
10  2.2
7.0–15
15  4.6
5.7–27
8.4  1.1
6.6–10
2.2  0.23
1.8–2.7
MON89034 180  33
140–240
73  18
49–120
39  11
24–58
10  2.2
5.6–14
13  4.7
3.0–20
8.4  0.96
6.7–10
2.1  0.32
1.6–2.8
Cry2Ab2 MON 87427 9
MON 89034 9
MIR162 9
MON 87411
200  23
150–240
150  28
110–200
52  19
21–83
27  7.0
12–37
47  13
20–77
0.57  0.083
0.45–0.75
2.3  0.37
1.5–3.0
MON89034 190  28
140–240
120  24
88–160
41  13
21–62
26  7.5
11–36
35  9.5
22–54
0.61  0.12
0.45–0.84
2.2  0.44
1.4–3.1
Vi3Aa20 MON 87427 9
MON 89034 9
MIR162 9
MON 87411
170  41
30–220
110  14
83–130
110  38
60–200
36  9.2
24–54
97  33
49–180
62  6.5
52–75
52  8.5
36–68
MIR162 220  31
170–310
110  26
45–140
95  25
65–150
35  8.2
20–52
98  20
73–150
64  4.9
57–75
54  10
38–71
PMI MON 87427 9
MON 89034 9
MIR162 9
MON 87411
8.8  2.7
1.5–14
9.4  2.1
6.6–15
6.3  3.1
2.8–14
2.9  0.99
1.6–5.1
5.2  1.7
2.7–9.5
2.5  0.26
2.0–3.1
1.3  0.23
0.91–1.8
MIR162 9.7  1.5
7.4–13
9.4  2.2
5.5–13
7.2  1.4
5.1–11
2.7  0.61
1.8–4.2
5.3  1.1
3.8–7.4
2.4  0.24
1.9–2.8
1.3  0.17
0.90–1.6
Cry3Bb1 MON 87427 9
MON 89034 9
MIR162 9
MON 87411
360  41
300–450
200  39
130–270
280  84
120–410
75  36
29–150
62  18
40–110
49  7.0
37–61
6.7  1.0
4.0–8.9
MON87411 310  48
200–410
180  52
45–250
260  80
130–440
72  29
26–130
56  17
24–85
50  8.1
36–69
7.2  4.7
4.2–27
(a): Number of samples is n = 20, except for: n = 1 for pollen (for CP4 EPSPS in MON 87427), n = 19 for OSL1 (for CP4EPSPS
and Cry3Bb1 in MON 87411) and n = 19 for OSL4 (for Vip3Aa20 and PMI in MIR162).
(b): Mean.
(c): Standard deviation.
(d): Range.
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Appendix B – Additional studies
List of additional studies performed by or on behalf of the applicant with regard to the evaluation of
the safety of maize MON 87427 9 MON 89034 9 MIR162 9 MON 87411 for humans, animal or the
environment
Study
identification
Title
MSL0022958 The Effect of Heat Treatment on Cry2Ab2 Immunodetection
SSB-507-07 A1 Evaluation of MIR162 Transgenic Maize Grain in a Broiler Chicken Feeding Study
MSL0027023 Amended Report for MSL0026697: Assessment of DvSnf7 RNA Levels in Maize Tissues
Collected from MON 87427 9 MON 89034 9 MIR162 9 MON 87411 Produced in the
United States Field Trials During 2014
MSL0026942 Assessment of DvSnf7 RNA Levels in Maize OSL1, OSL4, OSR1, Forage Root, Forage,
Pollen, and Grain Tissues Collected from MON 87427 9 MON 89034 9 MIR162 9
MON 87411 Produced in United States Field Trials During 2014
MSL0028504 Amended Report for MSL0028257: An Evaluation of the Potential for Interaction between
the Lepidopteran Insecticidal Traits in the Combined Maize Product MON 87427 9
MON 89034 9 MIR162 9 MON 87411 with Corn Earworm (Helicoverpa zea)
MSL0026614 Compositional Analyses of Maize Forage and Grain from MON 87427 9 MON 89034 9
MIR162 9 MON 87411 Grown in the United States in 2014
MSL0023074 The Effect of Heat Treatment on Cry3Bb1 Immunodetection
MSL0027526 Comparison of Lipid Transfer Protein (LTP) Expression Levels from MON 87427 9
MON 89034 9 MIR162 9 MON 87411 with Conventional Control Maize
MSL0022940 Immunodetection of Cry1A.105 Following Heat Treatment
MSL0028515 Amended Report for MSL0028185: Assessment of CP4 EPSPS, Cry1A.105, Cry2Ab2,
Cry3Bb1, Vip3Aa20 and PMI Protein Levels in Maize Tissues Collected from MON 87427 9
MON 89034 9 MIR162 9 MON 87411, MON 87427, MON 89034, MIR162 and MON 87411
Produced in Brazilian Field Trials During Safrinha 2016
MSL00026328 Comparison of Broiler Performance and Carcass Parameters When Fed Diets Containing
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 (Stack), Control, or Reference Maize
Grain
MSL0028034 Amended Report for MSL0027183: An Evaluation for the Potential for Interaction between
the Lepidopteran and Coleopteran Traits Produced by the Combined Maize Product
MON 87427 9 MON 89034 9 MIR162 9 MON 87411 with the Corn Earworm (Helicoverpa
zea)
MSL0027182 An Evaluation of the Protein for Interaction among Plant Incorporated Protectants Produced
by MON 87427 9 MON 89034 9 MIR162 9 MON 87411 with the Southern Corn Rootworm,
(Diabrotica undecimpunctata howardi)
MSL0028199 Assessment of DvSnf7 RNA Levels in Maize Tissues Collected from MON 87427 9
MON 89034 9 MIR162 9 MON 87411 and MON 87411 Produced in Brazilian Field Trials
during 2016
MSL0026733 Southern Blot Analyses to Confirm the Presence of MIR162 in the Combined Trait Maize
Product MON 87427 9 MON 89034 9 MIR162 9 MON 87411
MSL0027308 Southern Blot Analyses to Confirm the Presence of MON 87427, MON 89034 and
MON 87411 in the Combined Trait Maize Product MON 87427 9 MON 89034 9 MIR162 9
MON 87411
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